Merck Animal Health announced the commercial availability of CIRCUMVENT CL vaccine, a ready-to-use vaccine formulated to protect pigs three weeks of age and older against disease caused by Porcine Circovirus (PCV) Types 2a and 2d and Lawsonia intracellularis, the company wrote.
“CIRCUMVENT CL is designed to simplify herd health programs by delivering dual protection in a ready-to-use formulation that requires no mixing or reconstituting,” Merck says. “This new product complements Merck Animal Health’s existing swine portfolio, including CIRCUMVENT CML, a single-dose, ready-to-use vaccine that protects against PCV Types 2a and 2d, Mycoplasma hyopneumoniae (M. hyopneumoniae) and Lawsonia intracellularis in pigs three weeks of age and older, which was introduced in 2023.”
CIRCUMVENT CL leaves out the mycoplasma component to meet the needs of herds that are now M. hyopneumoniae-negative while maintaining robust protection against PCV and Lawsonia intracellularis.
“Merck Animal Health is committed to delivering innovative, practical solutions that help veterinarians and producers protect herd health while streamlining on-farm operations,” says Brett O’Brien, V.M.D., swine technical services, Merck Animal Health. “CIRCUMVENT CL provides trusted protection against two of the most significant enteric and systemic disease agents impacting swine production in a ready-to-use formulation. By offering options such as CIRCUMVENT CML and CIRCUMVENT CL, we enable tailored vaccination strategies that simplify vaccine handling and administration.”
Merck says the key product benefits of CIRCUMVENT CL include:
•Dual protection: Effective against disease caused by Porcine Circovirus Types 2a and 2d and Lawsonia intracellularis in pigs three weeks of age or older.
•Ready-to-use: Single-bottle presentation requires no mixing or reconstituting, helping to reduce preparation time and potential handling errors.
•Flexible herd options: Designed for use in herds where M. hyopneumoniae vaccination is not required, providing a targeted solution for M. hyopneumoniae-negative operations.
•Complementary portfolio: Adds to Merck Animal Health’s CIRCUMVENT family, enabling veterinarians to choose the formulation that best fits herd health status and management goals.
This product is available in 50- and 250-dose presentations. A 500-dose presentation will be available in Q1 2026, Merck says. For more information, click here.
